Global Information
회사소개 | 문의

간세포암종 : 파이프라인 리뷰

Hepatocellular Carcinoma - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 05월 상품 코드 229736
페이지 정보 영문 1275 Pages
가격
US $ 2,500 ₩ 2,858,500 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,717,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,575,500 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


간세포암종 : 파이프라인 리뷰 Hepatocellular Carcinoma - Pipeline Review, H1 2018
발행일 : 2018년 05월 페이지 정보 : 영문 1275 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

간세포 암종(HCC)은 여성보다 남성에게 이환되기 쉬운 경향이 있는 암으로 증상은 복부(특히 우상부) 통증, 반점이 잘 생기는 것, 잦은 출혈, 복부 팽만감, 황달 등입니다. 간세포 암종 발병의 주원인은 알콜 대량 섭취, 간장의 자가면역질환, B형 또는 C형 간염 바이러스 감염, 장기간의 만성적인 간장 염증, 철의 체내 과다 축적(헤모크로마토시스) 등입니다.

간세포 암종(HCC: Hepatocellular Carcinoma) 치료제의 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향 등을 전해드립니다.

서론

  • 조사 범위

간세포암종 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

간세포암종 : 기업에서 개발중인 치료제

간세포암종 : 대학/기관에서 연구중인 치료제

간세포암종 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

간세포암종 : 기업에서 개발중인 제품

간세포암종 : 대학/기관에서 연구중인 제품

간세포암종 치료제 개발에 참여하고 있는 기업

간세포암종 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 개요

간세포암종 : 최근의 파이프라인 동향

간세포암종 : 휴지 상태인 프로젝트

간세포암종 : 개발이 중지된 제품

간세포암종 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 16.09.30

List of Tables

  • Number of Products under Development for Hepatocellular Carcinoma, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Abivax SA, H1 2018
  • Hepatocellular Carcinoma - Pipeline by ACEA Biosciences Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Alnylam Pharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by American Gene Technologies International Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Amgen Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by ArQule Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Bavarian Nordic A/S, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Bayer AG, H1 2018
  • Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by CARsgen Therapeutics Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by CBT Pharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Celgene Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Cellular Biomedicine Group Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Celsion Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Conatus Pharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Curevac AG, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H1 2018
  • Hepatocellular Carcinoma - Pipeline by eFFECTOR Therapeutics Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Eiger BioPharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Eli Lilly and Co, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Epizyme Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Eureka Therapeutics Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H1 2018
  • Hepatocellular Carcinoma - Pipeline by GC Pharma, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Genelux Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Genentech Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Genosco Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Immunicum AB, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H1 2018

List of Figures

  • Number of Products under Development for Hepatocellular Carcinoma, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2018, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 18, 76, 60, 1, 3, 92, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 10, 6, 1, 1, 25 and 1 molecules, respectively.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hepatocellular Carcinoma - Overview
  • Hepatocellular Carcinoma - Therapeutics Development
  • Hepatocellular Carcinoma - Therapeutics Assessment
  • Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
  • Hepatocellular Carcinoma - Drug Profiles
  • Hepatocellular Carcinoma - Dormant Projects
  • Hepatocellular Carcinoma - Discontinued Products
  • Hepatocellular Carcinoma - Product Development Milestones
  • Appendix
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research